Pharmacokinetics and safety of a unilamellar liposomal formulation of amphotericin B (AmBisome) in rabbits
Open Access
- 1 April 1994
- journal article
- research article
- Published by American Society for Microbiology in Antimicrobial Agents and Chemotherapy
- Vol. 38 (4) , 713-718
- https://doi.org/10.1128/aac.38.4.713
Abstract
A unilamellar liposomal formulation of amphotericin B (LAmB) known as AmBisome was safely administered intravenously to 20 rabbits at 0.5, 1.0, 2.5, 5, or 10 mg/kg of body weight, whereas of 12 rabbits given desoxycholate amphotericin B (DAmB) intravenously at 0.5, 1.0, or 1.5 mg/kg, 2 died of acute cardiac toxicity when DAmB was administered at the highest dose. Single-dose LAmB (1 mg/kg) achieved a maximum concentration in serum (Cmax) of 26 +/- 2.4 micrograms/ml and an area under the curve to infinity (AUC0-infinity) of 60 +/- 16 micrograms.h/ml, while single-dose DAmB (1.0 mg/kg), by comparison, achieved a lower Cmax (4.7 +/- 0.2 micrograms/ml; P = 0.001) and a lower AUC0-infinity (30.6 +/- 2.2 micrograms.h/ml; P = 0.07). Following administration of a single dose of LAmB (10 mg/kg), a disproportionately higher Cmax (287 +/- 14 micrograms/ml) and AUC0-infinity (2,223 +/- 246 micrograms.h/ml) occurred, indicating saturable elimination. After chronic dosing (n = 4) with LAmB at 5.0 mg/kg/day for 28 days or DAmB at 1.0 mg/kg/day for 28 days, LAmB achieved daily peak levels of 122.8 +/- 5.8 micrograms/ml and trough levels of 34.9 +/- 1.8 micrograms/ml, while DAmB reached a peak of only 1.76 +/- 0.11 microgram/ml and a trough of 0.46 +/- 0.04 microgram/ml (P < or = 0.001). Significant accumulations of amphotericin B into reticuloendothelial organs were observed, with 239 +/- 39 micrograms/g found in the liver after chronic LAmB dosing (5 mg/kg/day), which was seven times higher than the 33 +/- 6 micrograms/g after DAmB dosing (1 mg/kg/day) (P = 0.002). Accumulation in kidneys, however, remained 14-fold lower (P =0.04) following LAmB dosing (0.87 +/- 0.61 microgram/g) than after DAmB dosing (12.7 +/- 4.6 microgram/g). Nephrotoxicity occurred in only one of four LAmB treated animals, while it occurred in all four chronically DAmB-treated animals: mild hepatozicity with transaminase elevations was seen in one LAmB-treated rabbit. We conclude that LAmB safely achieved higher Cmax(s) and AUC0-infinity(s) and demonstrated saturable, nonlinear elimination from plasma via reticuloendothelial organ uptake. Take reduced nephrotoxicity of LAmB correlated with diminished levels of amphotericin B in the kidneys.Keywords
This publication has 12 references indexed in Scilit:
- Efficacy of amphotericin B encapsulated in liposomes (AmBisome) in the treatment of invasive fungal infections in immunocompromised patientsJournal of Antimicrobial Chemotherapy, 1991
- Pharmacology and toxicology of a liposomal formulation of amphotericin B (AmBisome) in rodentsJournal of Antimicrobial Chemotherapy, 1991
- Overview of liposomesJournal of Antimicrobial Chemotherapy, 1991
- Experience with liposomal amphotericin B (AmBisome) in cryptococcal meningitis in AIDSJournal of Antimicrobial Chemotherapy, 1991
- Liposomal amphotericin B (AmBisome) in the treatment of fungal infections in neutropenic patientsJournal of Antimicrobial Chemotherapy, 1991
- Liposomal amphotericin B (AmBisome): safety data from a phase II/III clinical trialJournal of Antimicrobial Chemotherapy, 1991
- High-performance liquid chromatographic determination of amphotericin B in human serumJournal of Chromatography B: Biomedical Sciences and Applications, 1987
- CLINICAL-PHARMACOLOGY OF TC-99M-LABELED LIPOSOMES IN PATIENTS WITH CANCER1984
- Liposomal Blockade of the Reticuloendothelial System: Improved Tumor Imaging with Small Unilamellar VesiclesScience, 1983
- Liposome disposition in vivoBiochimica et Biophysica Acta (BBA) - Lipids and Lipid Metabolism, 1981